Pre-infusion 18F-FDG PET/CT for Prognostic and Toxicity Prediction in B-cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-cell Therapy
The pretreatment PET/CT parameter SUVmax appears to be a promising predictive factor for efficacy and prognosis, as well as being associated with the occurrence of CRS. Consequently, we can conclude that this metabolic parameter from pretreatment PET/CT scans may serve as a valuable tool in guiding patient selection for CAR-T therapy and predicting potential side effects.
Authors
- Xilan Yao
- Shuang Yao (ORCID: https://orcid.org/0000-0003-3686-5404)
- Jigang Yang (ORCID: https://orcid.org/0000-0002-0538-7676)
- Lei Xiao (ORCID: https://orcid.org/0000-0002-0428-1749)
- Hongrong Wang (ORCID: https://orcid.org/0000-0002-4980-1082)
- Wei Wang (ORCID: https://orcid.org/0000-0001-8990-5516)
Institutions
- Capital Medical University (CN)
- Beijing Friendship Hospital (CN)
- Beijing Fengtai Hospital (CN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1097/rlu.0000000000005888
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05